Literature DB >> 2051021

Human mast cell carboxypeptidase. Selective localization to MCTC cells.

A M Irani1, S M Goldstein, B U Wintroub, T Bradford, L B Schwartz.   

Abstract

Two murine mAb were prepared against human mast cell carboxypeptidase (HMC-CP) purified from human skin, and were termed CP1 and CP2, respectively. Double immunohistochemical labeling of Carnoy's-fixed sections of human skin, lung, and gastrointestinal tissue with CP1 and CP2, respectively, and with a murine monoclonal antitryptase antibody demonstrated that HMC-CP was selectively present in a subset of human mast cells. Double labeling experiments with CP1 and CP2, respectively, and a murine anti-chymase mAb demonstrated the presence of HMC-CP in the tryptase-positive, chymase-positive mast cell type (MCTC) only. Immunohistochemical labeling of peripheral blood leukocytes resulted in staining of monocytes with CP2 but not with CP1. In addition to chymase and a cathepsin-G like proteinase, HMC-CP is another neutral protease that is selectively present in the MCTC tryptase-positive, chymase-positive mast cells type of mast cell, thus extending the biochemical definition of human mast cell heterogeneity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2051021

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  Characterization of human mast cells developed in vitro from fetal liver cells cocultured with murine 3T3 fibroblasts.

Authors:  A A Irani; S S Craig; G Nilsson; T Ishizaka; L B Schwartz
Journal:  Immunology       Date:  1992-09       Impact factor: 7.397

2.  Stem cell factor-dependent human cord blood derived mast cells express alpha- and beta-tryptase, heparin and chondroitin sulphate.

Authors:  G Nilsson; T Blom; I Harvima; M Kusche-Gullberg; K Nilsson; L Hellman
Journal:  Immunology       Date:  1996-06       Impact factor: 7.397

3.  Characterization of a novel human mast cell line that responds to stem cell factor and expresses functional FcεRI.

Authors:  Tanya M Laidlaw; John W Steinke; Adrienne M Tiñana; Chunli Feng; Wei Xing; Bing K Lam; Sailaja Paruchuri; Joshua A Boyce; Larry Borish
Journal:  J Allergy Clin Immunol       Date:  2011-02-01       Impact factor: 10.793

4.  Experimental Arthritis Is Dependent on Mouse Mast Cell Protease-5.

Authors:  Richard L Stevens; H Patrick McNeil; Lislaine A Wensing; Kichul Shin; G William Wong; Philip M Hansbro; Steven A Krilis
Journal:  J Biol Chem       Date:  2017-02-13       Impact factor: 5.157

Review 5.  Mast cell peptidases: chameleons of innate immunity and host defense.

Authors:  Neil N Trivedi; George H Caughey
Journal:  Am J Respir Cell Mol Biol       Date:  2009-11-20       Impact factor: 6.914

6.  Phenotypic evaluation of cultured human mast and basophilic cells and of normal human skin mast cells.

Authors:  K Hamann; J Grabbe; P Welker; N Haas; B Algermissen; B M Czarnetzki
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

Review 7.  Mast cell proteases as pharmacological targets.

Authors:  George H Caughey
Journal:  Eur J Pharmacol       Date:  2015-05-07       Impact factor: 4.432

Review 8.  Potential effector and immunoregulatory functions of mast cells in mucosal immunity.

Authors:  L L Reber; R Sibilano; K Mukai; S J Galli
Journal:  Mucosal Immunol       Date:  2015-02-11       Impact factor: 7.313

9.  Increased CCL24/eotaxin-2 with postnatal ozone exposure in allergen-sensitized infant monkeys is not associated with recruitment of eosinophils to airway mucosa.

Authors:  Debbie L Chou; Joan E Gerriets; Edward S Schelegle; Dallas M Hyde; Lisa A Miller
Journal:  Toxicol Appl Pharmacol       Date:  2011-09-12       Impact factor: 4.219

Review 10.  Development of mast cells and importance of their tryptase and chymase serine proteases in inflammation and wound healing.

Authors:  Jeffrey Douaiher; Julien Succar; Luca Lancerotto; Michael F Gurish; Dennis P Orgill; Matthew J Hamilton; Steven A Krilis; Richard L Stevens
Journal:  Adv Immunol       Date:  2014       Impact factor: 3.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.